AzTrials
AzTrials

Prelabor Rupture of MembranesRESIRUPTNCT07301957

Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins

A study testing Additional rupture of the residual membrane in people with Prelabor Rupture of Membranes, run by Centre Hospitalier le Mans at 2 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Approximately 25% of patients experience premature rupture of membranes before labour. Of these patients, 82% will give birth within 24 hours and 97% within 48 hours. Patients who do not go into labour spontaneously will be induced 24 or 48 hours after their membranes rupture, depending on the centre. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Prelabor Rupture of Membranes
What is being tested?
Additional rupture of the residual membrane
Could I receive a placebo?
No, everyone receives an active treatment
How many people
130 participants
Where
2 sitesFrance
Study dates
24 Mar 2026to 24 Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Women over 18 years of age
  • Single foetal pregnancy, cephalic presentation
  • diagnosis of membrane rupture with persistence of one membrane and absence of immediate spontaneous labour.
  • Person affiliated with or beneficiary of a social security scheme
  • Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Who cannot join

  • Minor patient
  • patient under guardianship/curatorship,
  • multiple pregnancy, pregnancy with foetal death
  • non-cephalic presentation
  • gestational age less than 37 weeks,
  • rupture of membranes more than 12 hours ago
Show all 13Show fewer
  • contraindication to vaginal deliver
  • meconium-stained amniotic fluid,
  • clinical signs suggestive of intrauterine infection (maternal hyperthermia >38°C, maternal and/or foetal tachycardia, purulent amniotic fluid),
  • cervix not accessible for artificial rupture
  • vaginismus
  • contraindication to a potential expectant management
  • indication for induction for another reason

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

France2 sites, 2 recruiting
  • CHU Angers

    Angers, 49000

    Pierre-Emmanuel BOUET, MD, +33241354215, pierreemmanuel.bouet@chu-angers.fr

    Pierre-Emmanuel BOUET, MD

    Recruiting
  • Centre Hospitalier Le Mans

    Le Mans, 72000

    Christelle JADEAU, +33244710204, recherchecliniquepromotion@ch-lemans.fr

    Marie-Charlotte FAURANT, MD

    Recruiting

Other trials in France

About this study

Approximately 25% of patients experience premature rupture of membranes before labour. Of these patients, 82% will give birth within 24 hours and 97% within 48 hours.

Patients who do not go into labour spontaneously will be induced 24 or 48 hours after their membranes rupture, depending on the centre.

Read more

During this period, they are hospitalised in the obstetrics department. The presence of a residual membrane appears to prolong the latency period before labour begins and the rate of induction, according to a pilot study conducted by investigator.

No study specifically addresses this topic. The various studies on "Rupture of Membranes Before Labour" assess its frequency of occurrence or the time before considering induction. They also assess the occurrence of maternal-foetal infection. This is no longer of interest today, as antibiotic prophylaxis has significantly reduced maternal-foetal infections.

Investigator would therefore like to assess the impact of additional rupture of the residual membrane upon the patient's admission on the latency before labour and the induction rate (for membrane rupture exceeding 48 hours.

Being tested
Additional rupture of the residual membrane
Keywords
prelabor rupture of membranes
Medical subject headings
Fetal Membranes, Premature Rupture

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Additional rupture of the residual membraneOther

    Additional rupture of the residual membrane using a sterile, single-use amniotic membrane piercer such as the Robé device

Study groups in NCT07301957
Study groupRoleWhat they receive
Additional rupture of the residual membraneExperimentalRupture of the residual membrane
Receives: Other: Additional rupture of the residual membrane
Standard of careNo interventionunbroken residual membrane

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Latency between the rupture of membranes and the onset of labour

    Latency is evaluated by the time in minutes between the rupture of membranes and the onset of labour. The diagnosis of rupture is the spontaneous loss of fluid through the vagina. The diagnosis of labour is defined by the onset of painful uterine contractions and cervical changes. The time recorded will be when the patient's cervix is 3 cm dilated.

    Measured: At labour onset (up to 6 days)

Secondary outcomes (1)
  1. Trigger rate for prolonged rupture of membranes

    Trigger rate for prolonged rupture of membranes was evaluated by absence of spontaneous labour 48 hours after the time H0 defined during the initial consultation (rupture of membrane's diagnosis)

    Measured: 48 hours after rupture of membranes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study start24 Mar 2026
  3. Primary completion24 Mar 2028 (estimated)
  4. Study completion24 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07301957
Sponsor's protocol ID
CHM-2023/S30/07
Acronym
RESIRUPT
Status last verified
Jun 2026
First submitted
24 Nov 2025
Last updated
1 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Additional rupture of the residual membrane in people with Prelabor Rupture of Membranes, run by Centre Hospitalier le Mans at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Christelle JADEAU (+33244710204, recherchecliniquepromotion@ch-lemans.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Latency between the rupture of membranes and the onset of labour (time frame: At labour onset (up to 6 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in